Brighton Jones LLC grew its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 83.2% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,642 shares of the medical research company’s stock after buying an additional 1,200 shares during the period. Brighton Jones LLC’s holdings in Amgen were worth $433,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of AMGN. TrimTabs Asset Management LLC lifted its position in shares of Amgen by 88.9% during the 1st quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock valued at $100,000 after buying an additional 288 shares in the last quarter. Alpha Omega Wealth Management LLC lifted its position in shares of Amgen by 19.0% during the 1st quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock valued at $103,000 after buying an additional 100 shares in the last quarter. Jackson Grant Investment Advisers Inc. lifted its position in shares of Amgen by 0.6% during the 1st quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock valued at $104,000 after buying an additional 4 shares in the last quarter. Nelson Roberts Investment Advisors LLC purchased a new position in shares of Amgen during the 1st quarter valued at about $121,000. Finally, Signature Estate & Investment Advisors LLC lifted its position in shares of Amgen by 13.6% during the 1st quarter. Signature Estate & Investment Advisors LLC now owns 794 shares of the medical research company’s stock valued at $130,000 after buying an additional 95 shares in the last quarter. 78.14% of the stock is currently owned by hedge funds and other institutional investors.

AMGN has been the topic of a number of analyst reports. ValuEngine cut Amgen from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and set a $203.00 price objective (up from $189.00) on shares of Amgen in a research report on Wednesday, July 26th. BidaskClub raised Amgen from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 23rd. BMO Capital Markets cut Amgen from an “outperform” rating to a “market perform” rating in a research report on Wednesday, July 26th. Finally, Argus lifted their price objective on Amgen from $180.00 to $195.00 and gave the company a “buy” rating in a research report on Thursday, July 27th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the company. Amgen presently has an average rating of “Buy” and a consensus price target of $186.04.

TRADEMARK VIOLATION NOTICE: “Brighton Jones LLC Has $433,000 Stake in Amgen Inc. (AMGN)” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/09/13/brighton-jones-llc-has-433000-stake-in-amgen-inc-amgn.html.

Amgen Inc. (AMGN) traded down 1.50% during trading on Wednesday, hitting $188.13. The stock had a trading volume of 1,370,362 shares. The company’s 50 day moving average is $173.95 and its 200-day moving average is $168.82. The company has a market cap of $137.27 billion, a PE ratio of 17.14 and a beta of 1.35. Amgen Inc. has a 12 month low of $133.64 and a 12 month high of $190.94.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, topping the Zacks’ consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The firm had revenue of $5.81 billion for the quarter, compared to the consensus estimate of $5.67 billion. During the same quarter last year, the business posted $2.84 earnings per share. The firm’s revenue was up 2.1% compared to the same quarter last year. On average, equities research analysts predict that Amgen Inc. will post $12.57 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Thursday, August 17th were given a dividend of $1.15 per share. The ex-dividend date of this dividend was Tuesday, August 15th. This represents a $4.60 dividend on an annualized basis and a yield of 2.41%. Amgen’s payout ratio is 41.93%.

Amgen Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Stock Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related stocks with our FREE daily email newsletter.